Searched for
TEVA
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...- Teva shows the flip side of rapidly growing corporate leverageTeva slashed its earnings goals for a second time this year and cut its dividend, too.
- Teva appoints Dipankar Bhattacharjee as Prez, CEO Global Generic GroupAs President and CEO of Teva Generics Europe, Bhattacharjee has a proven track record of improving revenues and profitability, significantl...
- DRL, Cipla, Aurobindo among others to buy products from TevaThe remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical mer...
- Dr. Reddy’s buys eight ANDAs from Teva for $350 millionDr. Reddy’s said the acquisition of ANDAs is contingent on closing of the Teva generics transaction and approval by the US Federal Trade Co...
- Israel's Teva buys Allergan generic drug company for $40.5 billionTeva Pharmaceutical Industries Ltd. says it is purchasing Dublin-based Allergan PLC's generic pharmaceuticals business for $40.5 billion.
- Mylan rejects Teva's $40 billion merger offer as undervaluedDrug major Mylan has rejected a $40 billion unsolicited merger offer from Israel's Teva Pharmaceutical Industries calling the bid undervalu...
- Teva offers to buy Mylan for $40.1 billionTeva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement.
- Cipla Medpro collaborates with Teva Pharma; stock gainsThe collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively sell Teva’s broad pharmaceutical product po...
- Venus Remedies ties up with Israel's Teva for anti-cancer drugChandigarh based Pharma major has entered into agreement with Israel-based generic drug maker Teva to sell anti- cancer drug in Canadian ma...
- Natco set for US launch of generic copy of Teva’s drugIf the Hyderabad-based company begins selling the drug now, it may face penal damages on losing the patent battle with Teva.
- Teva settles patent dispute with Orchid PharmaTeva has settled patent dispute with Orchid Chemicals & Pharma pertaining to Parkinson’s disease drug Azilect (rasagiline mesylate) in the ...
- Teva Pharma, P&G sets up OTC plant in GujaratIsrael-based Teva Pharmaceuticals, an $18 billion generic drug maker will set up OTC medicine facility in Gujarat in collaboration with Pro...
- Israel's Teva Pharmaceutical Industries to foray into India through JV with Proctor & GambleGlobal pharma giant, Teva Pharmaceutical Industries (TPI) shall foray into India through a joint venture with US based Proctor & Gamble (P&...
- Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drugNatco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug,...
- Jeremy Levin named as next CEO of Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries Ltd named Jeremy Levin of Bristol-Myers Squibb Coto to replace Shlomo Yanai as chief executive officer.
- Ranbaxy Laboratories falls on payment concerns to Teva Pharmaceuticals, delay in settlment with FDARanbaxy's share price fell 1.66% due to concerns about payment to Teva Pharmaceuticals and delay in settlement with US authorities.
- Teva to buy Taiyo stake for $460 million, bid for restTeva Pharmaceutical Industries Ltd agreed to buy 57% of Taiyo Pharmaceutical Industry Co Ltd. for $460 million and bid for the rest.
- Zydus drags Teva to court for antitrust violationsZydus Cadila, an Ahmedabad-based pharmaceutical company, has taken Teva Pharmaceuticals, the world’s largest generic drug maker, to court i...
- Terms didn’t fit stringent acquisition criteria: TevaTeva Pharmaceutical Industries said on Sunday it stopped pursuing the purchase of the generics unit of German drugs and chemicals group Mer...
Load More
